Hope everyone is paying thorough attention to the South Africa virus strain as well as the new UK. There is a higher possibility that the new ARDS virus strain there evades the vaccines (still low thankfully). Whilst we bicker thousands still die every day. Trials and regulatory progression are hard but absolutely questions have to be asked about MSB's application and we know the US authorities have been utterly inept in most aspects of this pandemic. The NIH not being exempt either.
If you read the clinical reports on stem-cells and their use in various ailments, MSB having 'success' in the various areas they've tried is not a surprise. They've just failed to convert to a major trial success. Few would argue the veracity of the GvHD results. Certainly not 9 out of 10 medical experts in the field - bar one who had more than a passing interest in a rival patent he owned.
ARDS and CHF clearly have some positives in there, we just have to wait for the data. I would not be entirely surprised to see Novartis and MSB push a refined and swift C-19 ARDS trial in Europe. Take the US authorities out of it. A clear well executed trial amidst a pandemic that continues to rage and will do so for the next six months despite all the hype over vaccines - vaccines that like most will likely require constant new approaches.
COVID-19 always required a three prong approach. Vaccines, treatment and social distancing/isolation. We still lack effective treatments.
MSB Price at posting:
$2.31 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)